Nitric oxide releasing drug candidate SB204 reduces colonization of the acne-causing bacteria Propionibacterium acnes (P. acnes) in the skin of healthy volunteers, according to a recent trial. This study, in combination with Novan Therapeutics' earlier findings regarding sebum production, suggests the formulation may be capable of targeting multiple factors in acne. The Phase 1, 30-subject study was conducted by Dr. James Leyden. Several subjects demonstrated a greater than 90 percent reduction of P. acnes when treated with SB204; no vehicle-treated subjects exhibited such a response. A statistically significant difference (p < 0.05) in P. acnes counts was observed between active and vehicle after two weeks. SB204 is currently being examined in a Phase 2 study for the treatment of acne. Results of that study are expected early 2014.